Tags

Type your tag names separated by a space and hit enter

The endocannabinoid system in neuropathological states.
Int Rev Psychiatry. 2009 Apr; 21(2):172-80.IR

Abstract

The endocannabinoid system (ECS) exerts important modulatory functions in the central nervous system (CNS), particularly the retrograde control of excitatory or inhibitory synapses, which enables this system to participate in the control of important neurobiological processes in healthy conditions. However, this physiological relevance acquires a maximal interest in neuropathological conditions affecting either the function or the structures of specific areas of the brain, conditions that have been associated with important changes in the activity of this modulatory system (e.g. losses of CB1 receptors (CB1R), up-regulation of CB2 receptors (CB2R), generation of endocannabinoids) that are susceptible to pharmacological adaptation. Among the group of brain disorders that have been associated with the endocannabinoid system, a special interest has been concentrated in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and ischemia. These three disorders will be reviewed here from the perspective of the types of changes experienced by the cannabinoid signalling in humans and cellular or animal models, and from a possible usefulness of certain cannabinoid compounds to alleviate symptoms and/or to delay their progression.

Authors+Show Affiliations

Laboratorio de Apoyo a la Investigacion, Fundacion Hospital Alcorcon-CIBERNED, Madrid, Spain. jromero@fhalcorcon.esNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

19367511

Citation

Orgado, José Martínez, et al. "The Endocannabinoid System in Neuropathological States." International Review of Psychiatry (Abingdon, England), vol. 21, no. 2, 2009, pp. 172-80.
Orgado JM, Fernández-Ruiz J, Romero J. The endocannabinoid system in neuropathological states. Int Rev Psychiatry. 2009;21(2):172-80.
Orgado, J. M., Fernández-Ruiz, J., & Romero, J. (2009). The endocannabinoid system in neuropathological states. International Review of Psychiatry (Abingdon, England), 21(2), 172-80. https://doi.org/10.1080/09540260902782828
Orgado JM, Fernández-Ruiz J, Romero J. The Endocannabinoid System in Neuropathological States. Int Rev Psychiatry. 2009;21(2):172-80. PubMed PMID: 19367511.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The endocannabinoid system in neuropathological states. AU - Orgado,José Martínez, AU - Fernández-Ruiz,Javier, AU - Romero,Julián, PY - 2009/4/16/entrez PY - 2009/4/16/pubmed PY - 2009/8/6/medline SP - 172 EP - 80 JF - International review of psychiatry (Abingdon, England) JO - Int Rev Psychiatry VL - 21 IS - 2 N2 - The endocannabinoid system (ECS) exerts important modulatory functions in the central nervous system (CNS), particularly the retrograde control of excitatory or inhibitory synapses, which enables this system to participate in the control of important neurobiological processes in healthy conditions. However, this physiological relevance acquires a maximal interest in neuropathological conditions affecting either the function or the structures of specific areas of the brain, conditions that have been associated with important changes in the activity of this modulatory system (e.g. losses of CB1 receptors (CB1R), up-regulation of CB2 receptors (CB2R), generation of endocannabinoids) that are susceptible to pharmacological adaptation. Among the group of brain disorders that have been associated with the endocannabinoid system, a special interest has been concentrated in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and ischemia. These three disorders will be reviewed here from the perspective of the types of changes experienced by the cannabinoid signalling in humans and cellular or animal models, and from a possible usefulness of certain cannabinoid compounds to alleviate symptoms and/or to delay their progression. SN - 1369-1627 UR - https://www.unboundmedicine.com/medline/citation/19367511/The_endocannabinoid_system_in_neuropathological_states_ L2 - http://www.tandfonline.com/doi/full/10.1080/09540260902782828 DB - PRIME DP - Unbound Medicine ER -